Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Thiourea Catalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN110143881B reveals a novel thiourea dioxide method for separating nitro compounds in boscalid synthesis, offering significant cost reduction and purity improvements for agrochemical manufacturers.
Patent CN111471017A reveals a green organocatalytic route for Ornidazole and Secnidazole, offering high purity, reduced waste, and cost-effective manufacturing for global supply chains.
Patent CN115947773A details a green, phosphorus-free synthesis for drospirenone intermediates. Discover cost-effective manufacturing and scalable supply chain solutions.
Patent CN118638038A reveals mild catalytic synthesis for high-purity pharmaceutical intermediates with significant cost reduction and supply chain reliability advantages.
Patent CN113121619B discloses mild glycosylation using Kass reagent. Achieve high yield, stereoselective phenolic glycosides for reliable pharmaceutical intermediate supply.
Patent CN118638038B reveals novel chiral isothiourea catalysis for high-purity indole amides. Enables cost reduction and scalable supply chain for pharmaceutical intermediates manufacturing.
Patent CN121045008A enables high-purity axial chiral biaryl amino phenol synthesis under mild conditions avoiding heavy metals for cost-effective pharmaceutical intermediate manufacturing.
Patent CN118638038B delivers high-yield synthesis of N-axis chiral indole amides with exceptional enantioselectivity enabling cost reduction in pharmaceutical manufacturing and robust supply chain solutions.
Recent patent reveals chiral isothiourea-catalyzed synthesis of N-axis chiral indole amides with mild conditions and high enantioselectivity enabling cost reduction and reliable supply for pharmaceutical intermediates.
Discover a scalable, high-yield synthesis of N-axis chiral indole amides with >95% ee and potent Hep G2 cytotoxicity. Reduce R&D costs and supply chain risks with our CDMO expertise.